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Corticotropin-releasing hormone (CRH) is secreted under stress and regulates the hypothalamic–pituitary–
adrenal axis. However, CRH is also secreted outside the brain where it exerts proinflammatory effects through
activation of mast cells, which are increasingly implicated in immunity and inflammation. Substance P (SP) is
also involved in inflammatory diseases. Human LAD2 leukemic mast cells express only CRHR-1 mRNA weakly.
Treatment of LAD2 cells with SP (0.5–2 mM) for 6 hours significantly increases corticotropin-releasing hormone
receptor-1 (CRHR-1) mRNA and protein expression. Addition of CRH (1 mM) to LAD2 cells, which are ‘‘primed’’
with SP for 48 hours and then washed, induces synthesis and release of IL-8, tumor necrosis factor (TNF), and
vascular endothelial growth factor (VEGF) 24 hours later. These effects are blocked by pretreatment with an NK-1
receptor antagonist. Treatment of LAD2 cells with CRH (1 mM) for 6 hours induces gene expression of NK-1 as
compared with controls. However, repeated stimulation of mast cells with CRH (1 mM) leads to downregulation
of CRHR-1 and upregulation in NK-1 gene expression. These results indicate that SP can stimulate mast cells and
also increase expression of functional CRHR-1, whereas CRH induces NK-1 gene expression. These results may
explain CRHR-1 and NK-1 expression in lesional skin of psoriatic patients.
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INTRODUCTION
Mast cells are ubiquitous in the human body and are critical
for allergic reactions (Theoharides and Kalogeromitros,
2006), and are also involved in innate (Abraham and St
John, 2010) and acquired immunity (Galli et al., 2005) during
which they secrete numerous vasoactive molecules, cyto-
kines, and proteases. Increasing evidence implicates mast
cells in inflammatory diseases, especially those exacerbated
by stress (Theoharides and Cochrane, 2004). Corticotropin-
releasing hormone (CRH) is secreted under stress and
activates the hypothalamic–pituitary–adrenal axis (Chrousos,
1995). CRH, CRH receptors (CRHRs), other neuropeptides
such as substance P (SP), mast cells, and other cells
communicate as part of a local network mimicking the
hypothalamic–pituitary–adrenal axis in the skin (Slominski
and Wortsman, 2000).
SP exerts its effects by binding to two specific G-protein-
coupled cell surface receptors, CRHR-1 and CRHR-2
(Chen et al., 1993; Liaw et al., 1996). Human mast cells
express CRHR-1, stimulation of which by CRH leads to
selective release of vascular endothelial growth factor (VEGF)
without degranulation from human mast cells (Cao et al.,
2005).
SP was originally isolated and characterized from the
brain (Carraway and Leeman, 1973), but is now known to be
widely distributed in many tissues, and is induced in many
inflammatory processes (O’Connor et al., 2004). SP was
known to be a potent mast cell trigger of rodent mast cells
(Fewtrell et al., 1982), but less was known of its effect on
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human mast cells. We have shown that SP induces release of
VEGF from human mast cells, an action augmented by IL-33
(Theoharides et al., 2010).
In this study we report that SP induces expression of
functional CRHR-1, whereas CRH induces NK-1 gene
expression on LAD2 human leukemic mast cells. Repeated
stimulation of mast cells with CRH leads to downregulation
of CRHR-1 and upregulation of NK-1 genes.
RESULTS
Effect of SP on CRHR-1 expression on LAD2 cells
LAD2 mast cells show weak gene expression of CRHR-1, but
CRHR-2 gene expression was below detection by the method
used. Addition of SP (0.5, 1, and 2mM) to LAD2 cells for
6 hours leads to statistically significant increase in CRHR-1
mRNA (Figure 1a). FACS analysis shows that 48 hours
following treatment with SP (0.5 and 1 mM), the expression
of CRHR-1 protein is also increased (Figure 1b). In order to
investigate if these findings are limited to the leukemic nature
of LAD2 mast cells, we repeated some of the experiments
using 10-week-old human umbilical cord blood–derived mast
cells (hCBMCs). (Gene expression of CRHR-14 CRHR-2 is
significantly induced (Figure 1c and d) following 6 hours of
treatment with SP 10 mM, with human placenta used as a
positive control because it expresses both CRHR-1 and
CRHR-2.) In contrast, human basophils do not express any
CRHR (results not shown).
CRH stimulates LAD2 cell secretion of VEGF, TNF, and IL-8
Addition of CRH (1 mM; lower concentration gave inconsistent
results) for 24 hours to LAD2 cells ‘‘primed’’ with SP (2 mM) for
48 hours leads to a statistically significant (Po0.05) more
VEGF release (429.4±47 pg per 106 cells by CRH alone to
700.2±37 pg per 106 cells in SP-primed cells). This increase
could not be because of any residual effect of the original SP
stimulation, because parallel tubes with cells treated with SP
alone washed at 48 hours and then incubated for another
24 hours without CRH had much less VEGF release compared
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Figure 1. Effect of substance P (SP) on corticotropin-releasing hormone
receptor-1 (CRHR-1) mRNA expression in human mast cells. LAD2 cell
expression of CRHR-1 (a) mRNA following treatment with SP (0.5, 1, and
2mM) for 6 hours and (b) protein following treatment with SP (0.5 and 1 mM) for
48 hours. The y-axis indicates ‘‘counts’’ of cells, whereas the x-axis indicates
log fluorescence intensity (n¼ 3, Po0.05). (c, d) The 10-week-old human
umbilical cord blood–derived mast cell (hCBMC) expression of CRHR-1 and
CRHR-2 mRNA before and after 6 hours of incubation with SP (10 mM) at
37 1C. Human placenta was used as a positive control for CRHR-1 and
CRHR-2. Gene expression was analyzed by reverse transcriptase-PCR

































































































































Figure 2. Corticotropin-releasing hormone (CRH) stimulates LAD2 cell
secretion of vascular endothelial growth factor (VEGF), tumor necrosis
factor (TNF), and IL-8. Release of (a) VEGF, (b) TNF, and (c) IL-8 following
stimulation with CRH (1 mM) for 24 hours after pretreatment with substance P
(SP; 2 mM) for 48 hours; in certain experiments, mast cells were pretreated with
NK-1 antagonist (ant, 20 mM for 30minutes before SP; n¼ 3, *Po0.05).
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The effect of SP on VEGF release is blocked by an NK-1
antagonist added 30minutes before SP (Figure 2a). Moreover,
CRH (1 mM) increases tumor necrosis factor (TNF; Figure 2b)
and IL-8 (Figure 2c) release from LAD2 cells (2.9±0.14 pg
per 106 cells and 0 pg per 106 cells to 86.4±11.1 pg per 106
cells and 41.7±5.1 pg per 106 cells in SP (2 mM)-primed cells,
respectively), and these effects are also blocked by the NK-1
antagonist (Figure 2b and c).
CRH stimulates truncated NK-1 gene expression
CRH and SP may be released together in inflammatory
diseases that worsen by stress. We therefore investigated if
CRH could affect NK-1 gene expression. Addition of CRH
(1 and 10 mM) to LAD2 cells for 6 hours results in a statistically
significant increase in gene expression of only truncated NK-
1 mRNA (Figure 3). The full-length NK-1 was not expressed
(data not shown).
Effect of repeated stimulation of LAD2 cells with CRH on
CRHR-1 and truncated NK-1 gene expression
We then investigated if repeated stimulation with CRH would
affect CRHR-1 or NK-1 gene expression. Repeated stimula-
tion of mast cells every 6 hours up to 24 hours with CRH
(1 mM) downregulates CRHR-1 mRNA expression (Figure 4a),
but upregulates NK-1 mRNA expression (Figure 4b).
DISCUSSION
This is the first report to our knowledge that SP can increase
both mRNA and protein expression of CRHR-1 on human
mast cells, the activation of which leads to IL-8, TNF, and
VEGF secretion. This effect of SP could not be due to the
leukemic nature of LAD2 cells because it was also present in
hCBMCs. Moreover, the effect of SP could not be nonspecific
because contrary to our findings, SP was previously reported
to decrease FceRI expression on human mast cells (McCary
et al., 2010). SP had previously been shown to induce
CRHR-1 expression in human astrocytoma 4373 MG cells
(Hamke et al., 2006).
CRH also induced mRNA expression of only the truncated
NK-1 on LAD2 cells which is known to be at least ten times
less sensitive than the full-length receptor (Tuluc et al.,
2009) and was recently shown to be associated with
pathological states (Tuluc et al., 2009). These findings could
be relevant for the pathogenesis of skin diseases that worsen
by stress (Slominski et al., 2007; Slominski, 2009), such as
psoriasis, where both SP (Remro¨d et al., 2007) and CRH
(Slominski et al., 2000; Tagen et al., 2007) have been
implicated.
We also report that overstimulation with CRH leads to
downregulation of CRHR-1 on LAD2 cells. This finding may
explain the fact that CRHR-1 gene expression is decreased in
lesional psoriatic skin, possibly because of chronic over-
stimulation (Tagen et al., 2009). Human skin expresses
primarily CRHR-1, whereas CRHR-2 protein is found only
in hair follicles and eccrine glands (Slominski et al., 2004). It
was previously shown that IL-1, IL-4, and lipopolysaccharide
could increase CRHR-2 expression on hCBMCs (Papadopou-
lou et al., 2005b). These results suggest that activation of
CRHR-1 and CRHR-2 may have different functions on the
same or different cells or tissues. For instance, activation of
these receptors was shown to have different actions on























Figure 3. Corticotropin-releasing hormone (CRH) stimulates mRNA
expression of NK-1 receptor. Treatment of LAD2 cells with CRH (1 and
10mM) for 6 hours induces gene expression of truncated NK-1 (n¼ 3,
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Figure 4. Effect of corticotropin-releasing hormone (CRH) on CRH receptor-
1 (CRHR-1) and NK-1 receptor mRNA expression. Repeated stimulation of
mast cells with CRH every 6 hours up to 24 hours (a) downregulates CRHR-1,
but (b) upregulates truncated NK-1 receptor gene expression (n=3, *Po0.05).
TACRIs, tachykinin recepter I short.
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(Agelaki et al., 2002; Tsatsanis et al., 2007). Moreover,
CRHR-1 was responsible for skin (Agren et al., 1976),
whereas CRHR-2 was responsible for bladder (Boucher
et al., 2010) and cardiac inflammation (Huang et al., 2009).
Moreover, whereas skin CRHR-1 was overexpressed in
chronic urticaria (Papadopoulou et al., 2005a), skin CRHR-
2 was overexpressed in affected areas of alopecia areata
(Katsarou-Katsari et al., 2001). It is, therefore, interesting that
hair root progenitor cells were recently shown to develop into
mature mast cells in response to CRH (Paus et al., 1994).
CRH secreted outside the brain has proinflammatory
actions (Karalis et al., 1991). Such proinflammatory activities
could mediate the action of lipopolysaccharide (Zbytek and
Slominski, 2007), or through mast cell activation leading to
increased vascular permeability (Theoharides et al., 1998).
CRH stimulates CRHR-1-dependent selective release of VEGF
without histamine from human mast cells (Cao et al., 2005).
Mast cell stimulation by SP and CRH would result in
secretion of proinflammatory cytokines that would recruit
and activate local immune accessory cells that would also
stimulate peripheral nerves (Theoharides et al., 2004). Some
of these cytokines may have synergistic action with SP and/or
CRH. For instance, we recently reported that the ability of SP
to stimulate VEGF release from human mast cells is
augmented by IL-33 (Theoharides et al., 2010). Mast cells
have been previously shown to release VEGF in response to
IgE (Boesiger et al., 1998; Grutzkau et al., 1998) and CRH
(Cao et al., 2005).
SP could be involved in the pathogenesis of inflammatory
skin disorders, such as psoriasis (Farber et al., 1986; Remro¨d
et al., 2007), which worsens by acute stress (Harvima et al.,
1996; Fortune et al., 2005). SP-positive nerve fibers are more
dense in psoriatic lesions compared with normal skin and
have an increased number of contacts with mast cells
(Al’Abadie et al., 1995; Naukkarinen et al., 1996; Chan
et al., 1997; Jiang et al., 1998), which are also increased in
lesional psoriatic skin (Harvima et al., 1993; O¨zdamar et al.,
1996). SP-positive nerve fibers making contact with mast
cells were increased by acute stress in mice (Peters et al.,
2005), leading to dermal mast cell degranulation (Paus et al.,
1995; Fortune et al., 2005; Kawana et al., 2006).
The ability of CRH and SP to induce VEGF release from
mast cells is also relevant to psoriasis. Psoriatic plaques
contain increased levels of VEGF compared with normal skin
(Simonetti et al., 2006; Yalcin et al., 2007; Heidenreich et al.,
2009), and the VEGF 121 isoform also causes vascular
permeability (Creamer et al., 2002; Zhang et al., 2005).
Several VEGF polymorphisms are associated with an in-
creased risk of developing psoriasis (Detmar, 2004; Barile
et al., 2006), and epidermal overexpression of VEGF in
transgenic mice led to a phenotype nearly identical to that of
psoriasis (Xia et al., 2003).
Mast cells, CRH, and SP have been implicated in a
brain–skin connection (Paus et al., 2006), and SP was shown
to be involved in stress-induced hair loss in mice (Arck et al.,
2005). In addition, regarding the role of CRH in a local skin
‘‘hypothalamic–pituitary–adrenal axis’’ (Slominski et al.,
2000), the present results indicate that CRH and SP have
proinflammatory actions not only on their own, but also by
augmenting the expression of their respective receptors on
human mast cells.
MATERIALS AND METHODS
Recombinant human stem cell factor was kindly donated by
Biovitrum AB (Stockholm, Sweden). SP and CRH were obtained
from Sigma-Aldrich (St Louis, MO). Anti-human CRHR-1-allophy-
cocyanin (APC) for FACS analysis and ELISA kits were from R&D
Systems (Minneapolis, MN). The NK-1 receptor antagonist L733, 060
was purchased from Sigma-Aldrich.
Human mast cell culture
LAD2 human mast cells (obtained from the National Institutes of
Health (NIH)) were cultured in serum-free media (StemPro-34;
Gibco, Grand Island, NY) supplemented with 2mM L-glutamine,
100 IUml–1 penicillin, 50 mgml–1 streptomycin, and 100ngml–1
recombinant human stem cell factor. For optimal cell growth,
LAD2 cell density was maintained between 0.5 106 and
1 106 cells per ml.
In order to obtain hCBMCs, human cord blood was obtained from
placenta during normal deliveries in accordance with the established
institutional guidelines (Kempuraj et al., 2004). Briefly, mononuclear
cells were isolated by layering heparin-treated cord blood onto
lymphocyte separation medium (INC Biomedical, Aurora, OH).
CD34þ progenitor cells were isolated from mononuclear cells by
positive selection of AC133 (CD133þ /CD34þ ) cells by magnetic
cell sorting (Miltenyi Biotech, Auburn, CA). hCBMCs were derived
by the culture of CD34þ progenitor cells with minor modifications.
For the first 6 weeks, CD34þ cells were cultured in AIM medium
(Gibco) supplemented with 100 ngml–1 recombinant human stem
cell factor, and after 6 weeks 50 ngml–1 IL-6 (Chemicon, Temecula,
CA) was added and cultured at 37 1C in 5% CO2 balanced air. Mast
cell viability was determined by Trypan blue (0.3%) exclusion.
Human basophils were obtained from American Type Culture
Collection (ATCC, Manassas, VA) and were cultured in Eagle’s
minimum essential medium from ATCC.
Human placenta, expressing both CRHR-1 and CRHR-2 (Florio
et al., 2000; Grammatopoulos, 2008), was obtained from the
division of Maternal-Fetal Medicine, Tufts Medical Center, under
exemption no. 4 of H1RB.
IL-8, TNF, and VEGF assays
LAD2 cells were washed with Dulbecco’s phosphate-buffered saline
and suspended in complete culture medium. LAD2 cells (2 105
cells in 200ml per well) were plated in 96-well flat-bottom Falcon
cell culture plates from Becton Dickinson (Franklin Lakes, NJ), and
then cells were incubated with the SP for 48 hours at 37 1C in 5%
CO2 incubator. CRH was added for 24 hours and the plates were
centrifuged. IL-8 or VEGF were measured in the supernatant fluid by
ELISA. The minimum detectable level of VEGF was 5 pgml–1.
Control cells were treated with equal volume of only culture
medium.
FACS analysis for CRH receptors
Mast cells were Fc-blocked by treatment with 1 mg of human IgG per
105 cells for 15minutes at room temperature before staining. APC-
conjugated CRHR-1 reagent was added to the Fc-blocked cells and
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were incubated for 30minutes at 4 1C. Following incubation,
unreacted CRHR-1 detection reagent was removed by washing.
Finally, the cells were resuspended in phosphate-buffered saline for
final flow cytometric analysis. As a control for analysis, cells in a
separate tube were treated with APC-labeled mouse IgG2A anti-
body. Analysis was performed using the FACS analyzer Amnis Image
Stream (Amnis, Seattle, WA).
Total RNA extraction and real-time PCR analysis
Total RNA was extracted from LAD2 mast cells or hCBMCs (106)
using the Qiagen RNeasy mini kit (Valencia, CA). RNA was then
used to perform first-strand complementary DNA synthesis. The
reaction (20 ml) was run at 25 1C for 10minutes, 37 1C for 50minutes,
and inactivated by heating at 70 1C for 15minutes. In order to
measure CRHR-1, CRHR-2, and truncated NK-1 receptor gene
expression, quantitative real-time PCR was performed using Taqman
and gene expression assays, probes obtained from Applied
Biosystems (Carlsbad, CA): CRHR-1 (Hs00366363_m1), CRHR-2
(Hs00266401_m1), NK-1 full length (Hs00185530_m1), and NK-1
truncated (AIV13FD); the sequences are proprietary and not released
by the company.
The cycling conditions consisted of 1 cycle at 50 1C for 2minutes,
1 cycle at 95 1C for 10minutes, 40 cycles at 95 1C for 15 seconds, 1
cycle at 60 1C for 1minute, 1 cycle at 95 1C for 15 seconds, 1 cycle at
60 1C for 30 seconds, and 1 cycle at 95 1C for 15 seconds. Relative
mRNA quality was determined from standard curves run with each
experiment, and the expression was normalized to glyceraldehyde-
3-phosphate dehydrogenase used as the endogenous control.
Positive control included complementary DNA for CRHR-1 and
CRHR-2 from hCBMCs and human placenta. Negative control
included the sample with water instead of template to check for
external contamination.
Statistical analysis
All conditions were performed in triplicate, and all experiments were
repeated at least three times (n¼ 3). Results are presented as
mean±SD. Data from stimulated and control samples were
compared using the unpaired two-tailed, Student’s t-test. Signifi-
cance of comparisons is denoted by Po0.05.
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